MEMO FROM THE FUTURE: OPHTHALMOLOGY SOFTWARE COMPANIES

The Platform Wars — June 2030

CONFIDENTIAL | The 2030 Report GLOBAL INTELLIGENCE CRISIS SERIES

SUMMARY: THE BEAR CASE vs. THE BULL CASE

Bear case: ophthalmology software startups struggle as large EHR vendors dominate. Bull case: companies building AI-driven diagnostic support and surgical planning tools for complex cases remained defensible.

EXECUTIVE SUMMARY

By June 2030, ophthalmology EHR and practice management software companies have undergone a Darwinian collapse and reconsolidation. Legacy platforms (Modernizing Medicine/EMA, Nextech, Compulink) built for fragmented, independent practices lost ground to large-group customization and to new AI-native platforms. Data ownership conflicts, interoperability failures, and the inability of legacy platforms to integrate AI diagnostics have created an opening for new entrants. The survivors are those that can serve mega-groups with customized, integrated solutions or those that built AI-first from the ground up. Legacy vendors face existential threats.

This is a story of technological and market disruption converging.

I. LEGACY EHR VENDORS: THE OBSOLESCENCE CRISIS

Modernizing Medicine (EMA): Lost the Mega-Group Race

Modernizing Medicine (privately held, owned by Allscripts) had dominated ophthalmology EHR pre-AI, with approximately 18-22% of US market share among practices with 20+ locations.

Market position (2026): - Customer base: ~850 practices - Estimated revenue: $280-320M annually - Gross margin: 65-70% (cloud-based SaaS model) - Net customer acquisition cost recovery: 18-24 months

What happened (2028-2030): 1. Loss of large group clients: When Bausch + Lomb, J&J, and Alcon consolidated practices, they demanded either: - Migration to their own proprietary systems, OR - Extensive customization of EMA to fit mega-group workflows

1. AI integration failure: Modernizing Medicine struggled to integrate third-party AI diagnostic systems into its EHR. Competing AI companies complained of integration difficulties, forcing practices to choose between AI diagnostics or EMA features.

2. Data ownership disputes: As practices consolidated, the question of "who owns the data?" became critical. Modernizing Medicine's architecture made data portability difficult, creating friction during M&A.

Financial impact (estimated): - Customer count: 850 practices (2026) → 480 practices (2030); -43% - Average contract value: $32K/year (2026) → $24K/year (2030); -25% - Estimated revenue: $300M (2026) → $95M (2030); -68%

Nextech: The Mid-Market Bloodbath

Nextech, another major EHR vendor serving practices with 10-50 locations, faced even worse disruption: - Customer base: 1,200 practices (2026) → 550 (2030); -54% - Revenue: $180M (2026) → $65M (2030); -64%

Nextech was vulnerable because: - It served mid-market practices that consolidate first (as opposed to serving both solo and mega-groups) - Its platform was not designed for mega-group complexity - AI integration was weak

Compulink, EyeCarePro, and Regional Vendors: Essential Extinction

Smaller EHR vendors (Compulink, EyeCarePro, RevMedx, and 20+ regional vendors) faced customer consolidation: - Total market (aggregate small vendors): $140M revenue (2026) → $45M (2030); -68% - Many exited ophthalmology entirely or were acquired at distressed valuations

Consolidation trends: - Bausch + Lomb acquired the billing/EHR division of a regional vendor (2029) - J&J rolled out a custom EHR across its acquired practices (2028-2029) - Alcon integrated Nextech into some acquired practices, but phased it out for unified platform

II. THE AI INTEGRATION CRISIS

Legacy Systems Cannot Integrate AI Effectively

The core problem: Legacy EHRs built for physician workflows (note-taking, order entry, billing) could not easily integrate AI diagnostic systems.

Integration challenges: 1. **Data format incompatibil

Bull Case Alternative: Proactive 2025-2026 Strategy

Bull Case (2025-2026 Strategy): Rather than react to these trends, proactive software_companies who invested in specialization, AI integration, and differentiation in 2025-2026 maintained competitive advantage and pricing power by 2030.

ity: AI systems require structured imaging data; legacy EHRs had unstructured document architecture 2. Real-time processing: AI diagnostic results need to appear instantly; legacy EHRs were built for asynchronous data entry 3. Workflow disruption: Where does the AI output appear in the clinical workflow? Before, during, or after the physician exam? 4. Liability/validation:** If AI makes a diagnostic suggestion, the EHR must create an audit trail proving the physician reviewed and accepted/rejected it

Example: Integrating diabetic retinopathy AI into Modernizing Medicine EMA - DR AI system flags a retinal image as "positive for microaneurysms" - How does this communicate to the EHR? Via HL7 message? API? Manual entry? - Where does it appear? In an alert? In a separate diagnostic panel? - What happens if the ophthalmologist disagrees with the AI? Is the disagreement logged? - Most legacy EHRs had no framework for this

By 2029, AI companies (Google Health, Retinal AI, Autonomous, others) began bypassing legacy EHRs and building: - Standalone AI diagnostic dashboards that integrate via API (not deep EHR embedding) - Direct cloud-to-cloud integration (AI system in cloud, EHR in clinic, API bridge) - This created interoperability gaps and data fragmentation

Practitioner frustration: Ophthalmologists at large groups using legacy EHRs + third-party AI complained of: - AI results appearing in separate tab/system (not embedded in clinical workflow) - No seamless integration between diagnostic imaging AI and the medical record - Manual documentation burden ("I have to enter the AI finding into the EHR separately")

Data Interoperability: The Competitive Disaster

When practices consolidated, data migration became critical. Legacy EHR vendors discovered: - Their proprietary data structures made migration expensive and error-prone - Mega-groups demanded data portability; EHR vendors reluctant to facilitate exodus - Some acquisition deals fell apart or were renegotiated due to data migration costs

By June 2030, data interoperability and portability had become a major selection criterion for large groups considering EHR systems.

III. THE EMERGENCE OF AI-NATIVE PLATFORMS

The New Wave: Cloud-First, AI-First EHRs

By 2028-2029, a new generation of EHR/practice management platforms emerged, built from the ground up for AI integration:

Key players: 1. Autonomous (formerly Autonomous Health): Ophthalmology-specific AI-native EHR, $150M Series B (2028) 2. Retinal AI / EyeThink: AI diagnostic platform with integrated practice management 3. Google Health + Practice Integration: Google Health built ophthalmology modules designed for AI-first workflows 4. **Amazon Clinic / Amazon Care expans

ion: Entered ophthalmology with cloud-native system 5. Specialized startups:** Focused on specific workflows (surgical planning, telehealth, outcomes reporting)

Why AI-native platforms succeeded: - Built cloud-first (scalable, no on-premise infrastructure burden) - Designed for AI integration (image databases, real-time processing, audit trails) - API-first architecture (interoperable with third-party AI systems) - Data portability built in (recognizing that consolidation would require migration)

Adoption by large groups (2029-2030): - Bausch + Lomb piloting Autonomous for some acquired practices (2029) - J&J evaluating Google Health ophthalmology modules - Alcon maintaining mix of legacy (Nextech) + proprietary systems, but evaluating AI-first alternatives

The Valuation Disparity

By June 2030, valuation gap between legacy and AI-native platforms was stark: - Legacy EHR vendors: trading at <1x revenue multiples (in decline) - AI-native platforms: valued at 6-10x revenue multiples (growth trajectory)

Example (hypothetical): - Modernizing Medicine: $95M revenue, valued at $380M (4x revenue decline from historical valuations) - Autonomous (private): estimated $40M revenue run-rate (2030), valued at $2.4-4.0B (60-100x revenue) based on growth potential

IV. PRACTICE MANAGEMENT SYSTEM DISRUPTION

Practice Management (PM) Software as Commodity

Practice management software (scheduling, billing, patient management) became increasingly commoditized: - Large groups deployed custom PM systems or integrated existing ones - Mid-market practices couldn't afford custom solutions - Small practices exited

By June 2030, PM software wasn't a primary selection criterion anymore—groups wanted integrated EHR + PM + AI, not separate best-of-breed solutions.

PM vendor consolidation: - Standalone PM vendors (Athena, eClinicalWorks for ophthalmology modules): lost standalone viability - Nextech: lost significant market share as large groups chose other EHR platforms with integrated PM - Custom integration became the norm for large groups (rather than relying on vendor integrations)

V. IMAGING PLATFORM INTEGRATION: THE NEW FRONTIER

Diagnostic Imaging as the Core Workflow

By 2030, imaging platforms (OCT, fundus photography, visual fields) + AI interpretation became THE critical clinical workflow.

Key imaging platforms emerging: 1. Zeiss FORUM: Imaging + AI integration platform 2. Topcon Stellaris: All-in-one imaging + analytics 3. Heidelberg Spectralis with AI modules: Late entrant, faced uphill battle 4. Alcon surgical imaging + AI: Integration through acquisition strategy 5. Google Lens / Apple Health Vision features: General-purpose health tech companies entering ophthalmology imaging

The shift: Imaging platforms with integrated AI started to REPLACE integrated EHR/PM systems as the primary clinical tool. The EHR became secondary (for note-taking, billing, follow-up scheduling).

Example workflow (June 2030):

1. Patient checks in via app → appointment confirmed
2. Technician captures images (OCT, fundus, visual field) via integrated imaging system
3. AI interprets images in real-time, flags findings
4. Physician reviews AI-interpreted images + patient history (pulled from EHR), makes clinical decisions
5. Physician documents findings in EHR, orders treatment
6. Billing/follow-up automated via integrated PM system

In this workflow, the imaging + AI system is primary; EHR is secondary.

VI. INTEROPERABILITY & STANDARDS: THE UNSOLVED PROBLEM

HL7 FHIR Adoption: Slow Progress

Healthcare interoperability standards (HL7 FHIR) were supposed to solve integration issues. By 2030, progress was slow: - Some EHR vendors adopted FHIR (Google, Amazon) - Legacy vendors resisted FHIR (viewing it as threatening lock-in advantage) - Ophthalmology-specific data standards remained underdeveloped

The result: Integration remained manual, expensive, and error-prone in many large groups.

Data Ownership Conflicts: Ongoing Dispute

A fundamental question remained unresolved: Who owns patient data when a practice consolidates? - Patient perspective: "It's my data; I should be able to access it and move it" - Legacy EHR vendor perspective: "You licensed our software; data stays in our system" - Large group perspective: "We own the practice and the patient relationship; data is ours" - Regulators: Mixed guidance; some pushed for patient portability, others stayed silent

By June 2030, data ownership conflicts were generating litigation and inhibiting some M&A activity.

VII. CANADIAN, UK & AUSTRALIAN SOFTWARE MARKET DYNAMICS

Canada: Slower Consolidation, Legacy System Persistence

Canadian practices consolidated more slowly, so legacy systems (Modernizing Medicine, Nextech) held on longer than in the US.

By June 2030, Canadian EHR/PM market was 3-4 years behind the US in AI-native platform adoption.

UK: NHS Systems Dominate, Limited Private Software Market

The UK National Health Service used its own EHR systems (EMIS, SystmOne) for the majority of ophthalmology care. Private practices used legacy UK-developed EHRs (Vision, Genesis).

By June 2030, UK private ophthalmology software market was small and fragmented; AI-native platform adoption was minimal.

Australia: Telehealth-First Platform Opportunity

Australian practices, distributed across vast geography, needed telehealth-capable systems. This created opportunity for platforms that prioritized remote diagnostics and asynchronous review.

By June 2030, Australian practices were slightly ahead of US in adopting telehealth-integrated EHR platforms.

VIII. THE REGULATORY & LIABILITY IMPLICATIONS

FDA and Software Regulation

As AI became embedded

in EHR/practice management workflows, FDA regulatory questions emerged: - Is an AI diagnostic system used within an EHR a "medical device" requiring FDA clearance? - If an EHR integrates AI, is the EHR vendor liable for AI diagnostic errors?

By June 2030, answers remained unclear: - FDA took a cautious approach: Some AI diagnostics were regulated as medical devices, others weren't, case-by-case - Software liability: Lawsuits emerged where patients claimed EHR/AI misses harmed them - Malpractice insurance: Rates for practices using integrated AI systems increased 10-15% (liability premium for AI use)

This regulatory uncertainty slowed adoption of fully-integrated AI + EHR systems.

IX. THE CONSOLIDATION ENDGAME (JUNE 2030)

Winners:

1. Google, Amazon: Large tech companies entering healthcare with cloud-native, AI-capable systems
2. Autonomous, Retinal AI, Specialized AI platforms: Built for the 2030 era
3. Zeiss, Topcon, Heidelberg (imaging + AI integration): Imaging platforms consolidating around AI
4. **Large groups' proprietary syst

ems:** Custom-built platforms dominating their organizations

Losers:

1. Modernizing Medicine/EMA: Lost market share, declining revenue, facing existential pressure
2. Nextech, Compulink, regional vendors: Largely extinct or in distress acquisition
3. Standalone billing/PM vendors: Disintermediated by integration
4. Legacy EHR vendors without AI strategy: Dying slowly as customers churn

X. THE FUTURE STATE (BEYOND JUNE 2030)

Predicted Consolidation (2030-2035)

• Mega-groups: Will either build proprietary systems or partner with one large AI-native platform (Autonomous, Google, Amazon)
• Regional groups: Will consolidate around regional preferred platforms (2-3 dominant regional systems)
• Small practices: Will become irrelevant (mostly extinct) or will use affordable cloud SaaS tools (limited feature set)
• Imaging vendors: Will increasingly bundle AI + imaging + basic PM, competing with EHR vendors

The Inevitable: Healthcare Tech Giants Dominate

By June 2030, it was clear that **healthcare EHR/practice management software was

being dominated by tech giants** (Google, Amazon, Apple) and specialized AI health companies (Autonomous, etc.).

Legacy healthcare IT vendors (Allscripts, Athena, Medidata) were gradually marginalized in ophthalmology and other specialties requiring AI integration.

END OF MEMO

The 2030 Report Global Intelligence Crisis Series | Confidential | June 2030

COMPARISON TABLE: BEAR CASE vs. BULL CASE OUTCOMES

End of Memo

Prepared by: The 2030 Report | Futurism Unit Classification: Speculative Analysis | June 2030 Projection

REFERENCES & DATA SOURCES

1. Bloomberg Ophthalmology Intelligence, 'AI Diagnostic Systems and Retinal Imaging,' June 2030
2. McKinsey Eye Care Services, 'Ophthalmology Practice Consolidation and Consolidators,' May 2030
3. Gartner Healthcare Technology, 'Digital Ophthalmology and Telemedicine Integration,' June 2030
4. IDC Ophthalmology, 'Electronic Health Record Integration and Decision Support AI,' May 2030
5. Deloitte Eye Care, 'Practice Efficiency and Automation in Ophthalmology,' June 2030
6. American Academy of Ophthalmology (AAO), 'Ophthalmology Workforce and Practice Economics,' June 2030
7. Ophthalmology Management Association, 'Practice Consolidation and Private Equity Involvement,' May 2030
8. Journal of Refractive Surgery, 'LASIK and Surgical Innovation Trends,' 2030
9. Eye Care Business Association, 'Retail Optometry and Direct-to-Consumer Models,' June 2030
10. Mergermarket Healthcare, 'Ophthalmology M&A Activity and Multiples,' May 2030
11. Private Equity Eye Care Fund, 'Ophthalmology Consolidation Strategy and Valuations,' June 2030
12. American Society of Cataract and Refractive Surgeons (ASCRS), 'Surgical Innovation and Outcomes,' June 2030